XML 11 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover Page - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2021
Feb. 04, 2022
Jun. 30, 2021
Cover [Abstract]      
Document Type 10-K/A    
Amendment Flag true    
Document Period End Date Dec. 31, 2021    
Document Fiscal Year Focus 2021    
Document Fiscal Period Focus FY    
Trading Symbol ALVR    
Entity Registrant Name ALLOVIR, INC.    
Entity Central Index Key 0001754068    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Current Fiscal Year End Date --12-31    
Document Annual Report true    
Document Transition Report false    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company true    
Entity Ex Transition Period false    
ICFR Auditor Attestation Flag false    
Entity Shell Company false    
Entity Public Float     $ 598.9
Entity Common Stock, Shares Outstanding   65,345,501  
Title of 12(b) Security Common Stock, par value $0.0001 per share    
Security Exchange Name NASDAQ    
Entity File Number 001-39409    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 83-1971007    
Entity Address, Address Line One 1100 Winter Street    
Entity Address, City or Town Waltham    
Entity Address, State or Province MA    
Entity Address, Postal Zip Code 02451    
City Area Code 617    
Local Phone Number 433-2605    
Documents Incorporated by Reference Portions of the Proxy Statement for the registrant’s 2022 Annual Meeting of Stockholders, or the Proxy Statement, which the Registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission not later than 120 days after the Registrant’s fiscal year end of December 31, 2021, are incorporated by reference into Part III of this Annual Report on Form
10-K.
    
Auditor Firm ID 34    
Auditor Name Deloitte & Touche LLP    
Auditor Location Boston, MA, USA    
Amendment Description AlloVir, Inc. (the “Company”) is filing this Amendment No. 1 to its Annual Report on Form 10-K (this “Amendment”) to amend its Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (the “Original Form 10-K”), originally filed with the Securities and Exchange Commission (the “Commission”) on February 10, 2022. We are filing this Amendment to (i) modify Part II, Item 9A. “Controls and Procedures,” to include Management’s Report on Internal Control over Financial Reporting, which was previously omitted from our Original Form 10-K, and (ii) correct Exhibits 31.1 and 31.2 with respect to paragraph 4(b) therein. As a result, this Amendment contains only the Cover Page to this Form 10-K/A, this Explanatory Note, Item 8, Item 9A, the Exhibit Index, the Signature Page, the revised certifications in Exhibits 31.1 and 31.2 and the required certifications required by the Sarbanes-Oxley Act of 2002 in connection with the filing of this Amendment. Except as described above, this Amendment does not alter or affect any other part or other information set forth in the Original Form 10-K. This Amendment does not reflect events that may have occurred subsequent to the filing of the Original Form 10-K or modify or update in any way disclosures made in the Original Form 10-K. Accordingly, this Amendment should be read in conjunction with the Original Form 10-K and the Company’s other filings with the SEC. The filing of this Amendment is not an admission that the Original Form 10-K, when filed, included any untrue statement of a material fact or omitted to state a material fact necessary to make a statement not misleading.